Celastrol-loaded polymeric mixed micelles shows improved antitumor efficacy in 4 T1 bearing xenograft mouse model through spatial targeting
- PMID: 38763310
- DOI: 10.1016/j.ijpharm.2024.124234
Celastrol-loaded polymeric mixed micelles shows improved antitumor efficacy in 4 T1 bearing xenograft mouse model through spatial targeting
Abstract
In this study, we have proposed a novel approach that combines hyaluronic acid (HA), folic acid (FA), and celastrol (CLS) within a polymeric micelle system (CLS-HF/MLs), offering a dual-action strategy against breast cancer. Polymeric mixed micelles were prepared through the thin-film hydration method, and comprehensive quality control parameters were established, encompassing particle size, polydispersity index, zeta potential, surface morphology, encapsulation efficiency, drug content, in vitro drug release, and storage stability assessment. The average particle size of CLS-HF/MLs micelles was found to be 120 nm and their drug loading and encapsulation efficiencies were 15.9 % and 89.52 %, respectively. The in vitro release data showed that the CLS-HF/MLs targeted mixed micelles displayed a prolonged release profile compared to the free drug. Additionally, the stability of the developed polymeric mixed micelles was maintained for up to 8 weeks of storage in terms of particle size and drug content. Furthermore, both flow cytometry and confocal laser scanning microscopy studies indicated a significant enhancement in the cellular uptake efficiency and cytotoxicity of CLS-HF/MLs mixed micelles against MCF-7 cell line. In terms of pharmacokinetic analysis, the half-life and AUC values of CLS-HF/MLs mixed micelles were found to be approximately 4.71- and 7.36-folds higher than the values of free drug (CLS), respectively. The CLS-HF/MLs micelles exhibited remarkable antitumor efficacy (almost complete ablation of the 4 T1-cell bearing tumor xenografts mouse model) due to the dual receptor (CD44 and folate) targeting effects with minimal side effects. When considering the cumulative findings of our present research, it becomes evident that mixed micelles designed for chemotherapy offer a promising and potentially effective therapeutic avenue for the treatment of breast cancer.
Keywords: Anti-tumor effect; Celastrol; Dual targeting; Mixed micelles; Pharmacokinetics.
Copyright © 2024 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Carrier-Free Nanomedicine Based on Celastrol and Methotrexate for Synergistic Treatment of Breast Cancer via Folate Targeting.Int J Nanomedicine. 2025 Jun 27;20:8291-8304. doi: 10.2147/IJN.S516921. eCollection 2025. Int J Nanomedicine. 2025. PMID: 40599402 Free PMC article.
-
Mitoxantrone- and Folate-TPGS2k Conjugate Hybrid Micellar Aggregates To Circumvent Toxicity and Enhance Efficiency for Breast Cancer Therapy.Mol Pharm. 2017 Apr 3;14(4):1082-1094. doi: 10.1021/acs.molpharmaceut.6b01009. Epub 2017 Feb 24. Mol Pharm. 2017. PMID: 28191959
-
Hepatoma-Targeting and ROS-Responsive Polymeric Micelle-Based Chemotherapy Combined with Photodynamic Therapy for Hepatoma Treatment.Int J Nanomedicine. 2024 Sep 16;19:9613-9635. doi: 10.2147/IJN.S475531. eCollection 2024. Int J Nanomedicine. 2024. PMID: 39309184 Free PMC article.
-
Preparation and evaluation of teniposide-loaded polymeric micelles for breast cancer therapy.Int J Pharm. 2016 Nov 20;513(1-2):118-129. doi: 10.1016/j.ijpharm.2016.09.005. Epub 2016 Sep 3. Int J Pharm. 2016. PMID: 27596115
-
Advancements in Betulinic Acid-Loaded Nanoformulations for Enhanced Anti-Tumor Therapy.Int J Nanomedicine. 2024 Dec 29;19:14075-14103. doi: 10.2147/IJN.S493489. eCollection 2024. Int J Nanomedicine. 2024. PMID: 39748899 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous